Absolute Quantitation of Myocardial Blood Flow in Human Subjects With or Without Myocardial Ischemia Using Dynamic Flurpiridaz F 18 PET

Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer. A new absolute p...

Full description

Saved in:
Bibliographic Details
Published inJournal of Nuclear Medicine Vol. 55; no. 9; pp. 1438 - 1444
Main Authors Packard, René R.S., Huang, Sung-Cheng, Dahlbom, Magnus, Czernin, Johannes, Maddahi, Jamshid
Format Journal Article
LanguageEnglish
Published United States Society of Nuclear Medicine 01.09.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer. A new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress. In healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01). Absolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion.
AbstractList Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer. A new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress. In healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01). Absolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion.
Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer. A new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress. In healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01). Absolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion.
Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer.UNLABELLEDAbsolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer.A new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress.METHODSA new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress.In healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01).RESULTSIn healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with <50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with ≥50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between <50% and ≥50% stenosis vascular territories, were significant (P < 0.01).Absolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion.CONCLUSIONAbsolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion.
Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various shortcomings of available radiotracers. Flurpiridaz F 18 is a novel PET radiotracer that exhibits properties of an ideal tracer. A new absolute perfusion quantitation method with flurpiridaz was developed, taking advantage of the early kinetics and high first-pass extraction by the myocardium of this radiotracer, and the first-in-human measurements of MBF performed in 7 healthy subjects and 8 patients with documented CAD. PET images with time-activity curves were acquired at rest and during adenosine stress. In healthy subjects, regional MBF between coronary artery territories did not differ significantly, leading to a mean global MBF of 0.73 mL/min/g at rest and 2.53 mL/min/g during stress, with a mean global myocardial flow reserve (MFR) of 3.70. CAD vascular territories with 50% stenosis demonstrated a mean MBF of 0.73 at rest and 2.02 during stress, leading to a mean MFR of 2.97. CAD vascular territories with 50% stenosis exhibited a mean MBF of 0.86 at rest and 1.43 during stress, leading to a mean MFR of 1.86. Differences in stress MBF and MFR between normal and CAD territories, as well as between 50% and 50% stenosis vascular territories, were significant (P 0.01). Absolute quantitation of MBF in humans with the novel PET radiotracer flurpiridaz is feasible over a wide range of cardiac flow in the presence or absence of stress-inducible myocardial ischemia. The significant decrease in stress MBF and ensuing MFR in CAD territories allows a clear distinction between vascular territories exhibiting stress-inducible myocardial ischemia and those with normal perfusion.
Author Dahlbom, Magnus
Czernin, Johannes
Maddahi, Jamshid
Huang, Sung-Cheng
Packard, René R.S.
Author_xml – sequence: 1
  givenname: René R.S.
  surname: Packard
  fullname: Packard, René R.S.
– sequence: 2
  givenname: Sung-Cheng
  surname: Huang
  fullname: Huang, Sung-Cheng
– sequence: 3
  givenname: Magnus
  surname: Dahlbom
  fullname: Dahlbom, Magnus
– sequence: 4
  givenname: Johannes
  surname: Czernin
  fullname: Czernin, Johannes
– sequence: 5
  givenname: Jamshid
  surname: Maddahi
  fullname: Maddahi, Jamshid
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25071096$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1uEzEUhS1URNPCA7BBltiwSbjXGdvjZSlNW6kIEK1gZ3kmHupoxk79IxReoK_NpEklVAmJ1dl851xdfUfkwAdvCXmNMGNKyPcrXwa7nCFWM6wQ1PwZmTDkaioE-3FAJoACp5wDPyRHKa0AQNR1_YIcMg5y5MWE3J80KfQlW_q1GJ9dNtkFT0NHP21Ca-LSmZ5-6ENY0kUfflHn6UUZjKffSrOybU70u8u3NMSHDCX_3btM7a0dnKE3yfmf9OPGm8G141CJaxfd0vymC4o1_XJ2_ZI870yf7Kt9HpObxdn16cX06vP55enJ1bStgOdpw8GCsNIIaLjqmLK8YbLjnZRKqfG7BqrOcKwVVjWrmMCus5KbxiDWssL5MXm3213HcFdsynpwqbV9b7wNJWmUNXCoFPwHygWAqhnfom-foKtQoh8f2VI450w93H6zp0ozetPr6AYTN_rRxgjIHdDGkFK0nW73QnI0rtcIeutd77zr0bveeR-b-KT5OP7vzh_IWrAo
CODEN JNMEAQ
CitedBy_id crossref_primary_10_1007_s12350_020_02034_2
crossref_primary_10_1016_j_ccl_2015_07_013
crossref_primary_10_1007_s12350_023_03239_x
crossref_primary_10_1007_s12350_021_02873_7
crossref_primary_10_1002_mp_12398
crossref_primary_10_1007_s00259_016_3480_8
crossref_primary_10_1007_s12350_016_0763_1
crossref_primary_10_1007_s10554_018_1330_4
crossref_primary_10_1016_j_ccl_2023_01_003
crossref_primary_10_1007_s00259_021_05643_2
crossref_primary_10_1053_j_semnuclmed_2014_06_011
crossref_primary_10_2967_jnumed_115_164111
crossref_primary_10_1093_ehjci_jeab267
crossref_primary_10_1016_j_pcad_2015_01_001
crossref_primary_10_1007_s12350_015_0199_z
crossref_primary_10_1016_j_nuclcard_2024_101834
crossref_primary_10_1002_jmri_25604
crossref_primary_10_1002_ppap_201500099
crossref_primary_10_1007_s12350_020_02421_9
crossref_primary_10_1007_s12350_019_01694_z
crossref_primary_10_1007_s00259_016_3317_5
crossref_primary_10_1007_s11886_020_01368_0
crossref_primary_10_3389_fcvm_2022_919719
crossref_primary_10_1111_cpf_12708
crossref_primary_10_1161_CIRCRESAHA_116_307898
crossref_primary_10_1007_s12149_021_01601_y
crossref_primary_10_1109_TRPMS_2020_3010844
crossref_primary_10_1038_s44161_024_00587_w
crossref_primary_10_1007_s00259_015_3101_y
crossref_primary_10_1007_s00259_025_07174_6
crossref_primary_10_2967_jnumed_120_252007
crossref_primary_10_1007_s12350_016_0513_4
crossref_primary_10_1007_s12350_015_0300_7
crossref_primary_10_1007_s12350_020_02434_4
crossref_primary_10_1007_s10554_018_1469_z
crossref_primary_10_1007_s12350_022_02968_9
crossref_primary_10_1016_j_jjcc_2017_03_002
crossref_primary_10_17996_anc_18_00052
crossref_primary_10_1161_CIRCULATIONAHA_115_018089
crossref_primary_10_1007_s12350_017_1140_4
crossref_primary_10_3389_fphar_2015_00227
crossref_primary_10_1007_s10741_017_9620_9
crossref_primary_10_1007_s12350_017_0909_9
crossref_primary_10_1007_s12149_017_1171_6
crossref_primary_10_1007_s11886_022_01713_5
crossref_primary_10_1007_s12350_020_02335_6
crossref_primary_10_1016_j_cpet_2020_09_004
crossref_primary_10_1016_j_tcm_2019_02_007
crossref_primary_10_1007_s12181_018_0266_1
crossref_primary_10_1155_2017_5246853
crossref_primary_10_1007_s12350_017_1131_5
crossref_primary_10_1007_s40336_018_0263_1
crossref_primary_10_1007_s00259_017_3684_6
crossref_primary_10_1016_j_nuclcard_2024_102072
Cites_doi 10.1016/j.nuclcard.2007.07.009
10.1016/j.nuclcard.2007.07.008
10.1161/CIRCIMAGING.108.815423
10.2967/jnumed.110.083196
10.2967/jnumed.111.092528
10.1016/j.jacc.2012.11.022
10.1016/j.nuclcard.2007.06.120
10.1016/j.jcmg.2010.04.007
10.1007/s12350-011-9491-8
10.1016/j.nuclcard.2004.04.005
10.1161/CIRCULATIONAHA.109.915009
10.1161/CIRCULATIONAHA.111.050427
10.2967/jnumed.110.081828
10.2967/jnumed.108.054395
10.2967/jnumed.107.044727
10.1161/CIRCULATIONAHA.108.797761
10.1016/j.jacc.2009.02.069
10.1016/j.jacc.2011.01.065
10.1007/s12350-012-9588-8
10.1016/j.jcmg.2011.12.014
10.1161/01.CIR.88.1.62
ContentType Journal Article
Copyright 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Copyright Society of Nuclear Medicine Sep 1, 2014
Copyright_xml – notice: 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
– notice: Copyright Society of Nuclear Medicine Sep 1, 2014
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
4T-
8FD
FR3
K9.
M7Z
NAPCQ
P64
7X8
7QO
DOI 10.2967/jnumed.114.141093
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Docstoc
Technology Research Database
Engineering Research Database
ProQuest Health & Medical Complete (Alumni)
Biochemistry Abstracts 1
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
Biotechnology Research Abstracts
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Nursing & Allied Health Premium
Technology Research Database
Docstoc
Biochemistry Abstracts 1
ProQuest Health & Medical Complete (Alumni)
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
Biotechnology Research Abstracts
DatabaseTitleList MEDLINE
Nursing & Allied Health Premium
MEDLINE - Academic
Engineering Research Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2159-662X
1535-5667
EndPage 1444
ExternalDocumentID 3429190251
25071096
10_2967_jnumed_114_141093
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
Feature
GrantInformation_xml – fundername: NHLBI NIH HHS
  grantid: T32 HL007895
GroupedDBID 123
18M
41~
5VS
96U
AAYXX
ACGFO
AEGXH
AIAGR
ALMA_UNASSIGNED_HOLDINGS
CITATION
GX1
N9A
RHI
TSM
U5U
W8F
---
-~X
.55
.GJ
29L
2WC
3O-
53G
5RE
7RV
7X7
88E
88I
8AF
8AO
8FE
8FG
8FH
8FI
8FJ
8R4
8R5
8WZ
A6W
ABEFU
ABSQV
ABUWG
ACGOD
ACIWK
ACPRK
ADDZX
ADMOG
AENEX
AFFNX
AFKRA
AFOSN
AFRAH
AHMBA
AI.
ALIPV
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
BKEYQ
BPHCQ
BVXVI
CCPQU
CGR
CS3
CUY
CVF
DIK
DU5
DWQXO
E3Z
EBD
EBS
ECM
EIF
EJD
EMOBN
EX3
F5P
F9R
FYUFA
GNUQQ
H13
HCIFZ
HMCUK
I-F
IL9
INIJC
J5H
KQ8
L7B
LK8
M1P
M2P
M2Q
M7P
N4W
NAPCQ
NPM
OK1
P2P
P62
PHGZT
PQQKQ
PROAC
PSQYO
Q2X
R0Z
RNS
RWL
S0X
SJN
SV3
TAE
TR2
TUS
UKHRP
VH1
WH7
WOQ
WOW
X7M
YHG
YQJ
ZGI
ZXP
4T-
8FD
FR3
K9.
M7Z
P64
7X8
7QO
ID FETCH-LOGICAL-c405t-b50e06e7a60b59f29e5b27f5f77999688b04fa518914824261ffe75aba1187413
ISSN 0161-5505
1535-5667
IngestDate Fri Jul 11 09:32:46 EDT 2025
Fri Jul 11 08:12:35 EDT 2025
Mon Jun 30 10:44:37 EDT 2025
Thu Apr 03 07:09:07 EDT 2025
Tue Jul 01 01:45:11 EDT 2025
Thu Apr 24 22:54:18 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords MBF
MFR
flurpiridaz
human
PET
Language English
License 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c405t-b50e06e7a60b59f29e5b27f5f77999688b04fa518914824261ffe75aba1187413
Notes SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://jnm.snmjournals.org/content/55/9/1438.full.pdf
PMID 25071096
PQID 1561352941
PQPubID 40808
PageCount 7
ParticipantIDs proquest_miscellaneous_1780504901
proquest_miscellaneous_1560098251
proquest_journals_1561352941
pubmed_primary_25071096
crossref_citationtrail_10_2967_jnumed_114_141093
crossref_primary_10_2967_jnumed_114_141093
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-09-00
2014-Sep
20140901
PublicationDateYYYYMMDD 2014-09-01
PublicationDate_xml – month: 09
  year: 2014
  text: 2014-09-00
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: New York
PublicationTitle Journal of Nuclear Medicine
PublicationTitleAlternate J Nucl Med
PublicationYear 2014
Publisher Society of Nuclear Medicine
Publisher_xml – name: Society of Nuclear Medicine
References 2021051712064055000_55.9.1438.20
2021051712064055000_55.9.1438.13
2021051712064055000_55.9.1438.12
2021051712064055000_55.9.1438.11
2021051712064055000_55.9.1438.10
2021051712064055000_55.9.1438.21
Johnson (2021051712064055000_55.9.1438.19) 2012; 5
2021051712064055000_55.9.1438.1
2021051712064055000_55.9.1438.2
2021051712064055000_55.9.1438.3
2021051712064055000_55.9.1438.4
2021051712064055000_55.9.1438.5
2021051712064055000_55.9.1438.17
2021051712064055000_55.9.1438.6
2021051712064055000_55.9.1438.16
2021051712064055000_55.9.1438.7
2021051712064055000_55.9.1438.15
2021051712064055000_55.9.1438.8
2021051712064055000_55.9.1438.14
2021051712064055000_55.9.1438.9
Nagamachi (2021051712064055000_55.9.1438.22) 1996; 37
2021051712064055000_55.9.1438.18
22007073 - Circulation. 2011 Nov 15;124(20):2215-24
21498538 - J Nucl Med. 2011 May;52(5):726-32
20541718 - JACC Cardiovasc Imaging. 2010 Jun;3(6):623-40
17826322 - J Nucl Cardiol. 2007 Sep-Oct;14(5):688-97
8862296 - J Nucl Med. 1996 Oct;37(10):1626-31
19808572 - Circ Cardiovasc Imaging. 2009 Mar;2(2):77-84
19380625 - Circulation. 2009 May 5;119(17):2333-42
23265345 - J Am Coll Cardiol. 2013 Jan 29;61(4):469-77
19573732 - J Am Coll Cardiol. 2009 Jul 7;54(2):150-6
18022105 - J Nucl Cardiol. 2007 Nov-Dec;14(6):789-98
18022104 - J Nucl Cardiol. 2007 Nov-Dec;14(6):782-8
8319357 - Circulation. 1993 Jul;88(1):62-9
20660808 - Circulation. 2010 Aug 10;122(6):603-13
19164219 - J Nucl Med. 2009 Feb;50(2):214-9
21441533 - J Nucl Med. 2011 Apr;52(4):617-24
22733534 - J Nucl Cardiol. 2012 Oct;19(5):1044-59
15295413 - J Nucl Cardiol. 2004 Jul-Aug;11(4):440-9
22498334 - JACC Cardiovasc Imaging. 2012 Apr;5(4):430-40
21849402 - J Nucl Med. 2011 Sep;52(9):1490-8
18344426 - J Nucl Med. 2008 Apr;49(4):630-6
21816311 - J Am Coll Cardiol. 2011 Aug 9;58(7):740-8
22259007 - J Nucl Cardiol. 2012 Feb;19 Suppl 1:S30-7
References_xml – ident: 2021051712064055000_55.9.1438.3
  doi: 10.1016/j.nuclcard.2007.07.009
– ident: 2021051712064055000_55.9.1438.4
  doi: 10.1016/j.nuclcard.2007.07.008
– ident: 2021051712064055000_55.9.1438.8
  doi: 10.1161/CIRCIMAGING.108.815423
– ident: 2021051712064055000_55.9.1438.7
  doi: 10.2967/jnumed.110.083196
– ident: 2021051712064055000_55.9.1438.9
  doi: 10.2967/jnumed.111.092528
– ident: 2021051712064055000_55.9.1438.10
  doi: 10.1016/j.jacc.2012.11.022
– ident: 2021051712064055000_55.9.1438.11
  doi: 10.1016/j.nuclcard.2007.06.120
– ident: 2021051712064055000_55.9.1438.1
  doi: 10.1016/j.jcmg.2010.04.007
– ident: 2021051712064055000_55.9.1438.2
  doi: 10.1007/s12350-011-9491-8
– ident: 2021051712064055000_55.9.1438.15
  doi: 10.1016/j.nuclcard.2004.04.005
– volume: 37
  start-page: 1626
  year: 1996
  ident: 2021051712064055000_55.9.1438.22
  article-title: Reproducibility of measurements of regional resting and hyperemic myocardial blood flow assessed with PET
  publication-title: J Nucl Med.
– ident: 2021051712064055000_55.9.1438.12
  doi: 10.1161/CIRCULATIONAHA.109.915009
– ident: 2021051712064055000_55.9.1438.18
  doi: 10.1161/CIRCULATIONAHA.111.050427
– ident: 2021051712064055000_55.9.1438.16
  doi: 10.2967/jnumed.110.081828
– ident: 2021051712064055000_55.9.1438.13
  doi: 10.2967/jnumed.108.054395
– ident: 2021051712064055000_55.9.1438.5
  doi: 10.2967/jnumed.107.044727
– ident: 2021051712064055000_55.9.1438.6
  doi: 10.1161/CIRCULATIONAHA.108.797761
– ident: 2021051712064055000_55.9.1438.14
  doi: 10.1016/j.jacc.2009.02.069
– ident: 2021051712064055000_55.9.1438.17
  doi: 10.1016/j.jacc.2011.01.065
– ident: 2021051712064055000_55.9.1438.20
  doi: 10.1007/s12350-012-9588-8
– volume: 5
  start-page: 430
  year: 2012
  ident: 2021051712064055000_55.9.1438.19
  article-title: Integrating noninvasive absolute flow, coronary flow reserve, and ischemic thresholds into a comprehensive map of physiological severity
  publication-title: JACC Cardiovasc Imaging.
  doi: 10.1016/j.jcmg.2011.12.014
– ident: 2021051712064055000_55.9.1438.21
  doi: 10.1161/01.CIR.88.1.62
– reference: 19380625 - Circulation. 2009 May 5;119(17):2333-42
– reference: 20541718 - JACC Cardiovasc Imaging. 2010 Jun;3(6):623-40
– reference: 23265345 - J Am Coll Cardiol. 2013 Jan 29;61(4):469-77
– reference: 15295413 - J Nucl Cardiol. 2004 Jul-Aug;11(4):440-9
– reference: 19573732 - J Am Coll Cardiol. 2009 Jul 7;54(2):150-6
– reference: 21849402 - J Nucl Med. 2011 Sep;52(9):1490-8
– reference: 19808572 - Circ Cardiovasc Imaging. 2009 Mar;2(2):77-84
– reference: 22733534 - J Nucl Cardiol. 2012 Oct;19(5):1044-59
– reference: 21441533 - J Nucl Med. 2011 Apr;52(4):617-24
– reference: 21816311 - J Am Coll Cardiol. 2011 Aug 9;58(7):740-8
– reference: 8319357 - Circulation. 1993 Jul;88(1):62-9
– reference: 18022104 - J Nucl Cardiol. 2007 Nov-Dec;14(6):782-8
– reference: 8862296 - J Nucl Med. 1996 Oct;37(10):1626-31
– reference: 18022105 - J Nucl Cardiol. 2007 Nov-Dec;14(6):789-98
– reference: 17826322 - J Nucl Cardiol. 2007 Sep-Oct;14(5):688-97
– reference: 22259007 - J Nucl Cardiol. 2012 Feb;19 Suppl 1:S30-7
– reference: 21498538 - J Nucl Med. 2011 May;52(5):726-32
– reference: 20660808 - Circulation. 2010 Aug 10;122(6):603-13
– reference: 22007073 - Circulation. 2011 Nov 15;124(20):2215-24
– reference: 22498334 - JACC Cardiovasc Imaging. 2012 Apr;5(4):430-40
– reference: 19164219 - J Nucl Med. 2009 Feb;50(2):214-9
– reference: 18344426 - J Nucl Med. 2008 Apr;49(4):630-6
SSID ssj0006888
ssj0062072
Score 2.3905604
Snippet Absolute quantitation of myocardial blood flow (MBF) by PET is an established method of analyzing coronary artery disease (CAD) but subject to the various...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 1438
SubjectTerms Aged
Cardiovascular disease
Coronary Circulation
Female
Fluorine Radioisotopes
Heart attacks
Humans
Ischemia
Male
Myocardial Ischemia - physiopathology
Nuclear medicine
Positron-Emission Tomography - methods
Pyridazines
Radiometry
Stress response
Tomography
Title Absolute Quantitation of Myocardial Blood Flow in Human Subjects With or Without Myocardial Ischemia Using Dynamic Flurpiridaz F 18 PET
URI https://www.ncbi.nlm.nih.gov/pubmed/25071096
https://www.proquest.com/docview/1561352941
https://www.proquest.com/docview/1560098251
https://www.proquest.com/docview/1780504901
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELfKkBAviP8UBjIST0QpSZY4zuMoqwaIaYxO7C2yU5t1lASFVoh-AT4eX4k7O3FTWCfGS9q69inN_Xrn--M7Qp5pjVXGwonPk6jwY6m5z0UU-0oFTIKG35ECI7rvDtj-cfzmJDnp9X51spYWczkolueeK_kfrsIY8BVPyV6Cs44oDMB74C9cgcNw_Sce70pDX2FqZjlvqm2bpJYfoKJqcybkJWame6NZ9R1dG9ZnD9LizGRxfEQvbFWbV0xQ7qx7DWav-jIVnk0qeGU71wMh4My0nk7E0ht5IfcO98YbNrgHWCrZlAlaD98fiuKzsBn1RyD0TKTeOxp8GKwg1jqxQRL5w1PVaFfjUD-dycq6ccWncuEsguFSoYunyS4WoD3WHBph7DK2nI-ThT4aTlZFmTHYmGQ-Y6bzuhPctr5vA9CsI4WxpXtHo4PNGJ-nLaKMYbz6rARiEyyaPMCkV9uwcb0y9x8a0-UxggWFRHJLAk9455bEFXI1ArsFW2q8fb8qX884dx9YFJjWYu7n2pg70nvx1y2t75o2mEJmSzS-SW40rKa7Fpi3SE-Vt8m1lt13yM8Wn7SLT1ppusIZNfikiE86LanBJ23xSRGXtKppg8_uuhaf1OCTNvikHXzSEQ05BXzeJcejvfFw328af_gF2A9zXyYBiAqVChbIJNNRphIZpTrRaYr2OecyiLVIQp5hFVt0Amit0kRIEWKLyXDnHtkqq1I9IFRGjCepFlKCBJJxAeaZYoEWIkxSGIn6JGgfbF40zwGbs8zyjbztk-duyVdbEuaiydstt_JGcnzLQ7TakyiLwz556r4GuY7BOlGqamHmYK1fMD8umIMNSTB0D3PuWyS4O4rQ0Asy9vAyd_uIXF_9I7fJ1rxeqMew6Z7LJwbIvwHlQdWF
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Absolute+Quantitation+of+Myocardial+Blood+Flow+in+Human+Subjects+With+or+Without+Myocardial+Ischemia+Using+Dynamic+Flurpiridaz+F+18+PET&rft.jtitle=Journal+of+Nuclear+Medicine&rft.au=Packard%2C+Ren%C3%A9+R.S.&rft.au=Huang%2C+Sung-Cheng&rft.au=Dahlbom%2C+Magnus&rft.au=Czernin%2C+Johannes&rft.date=2014-09-01&rft.issn=0161-5505&rft.eissn=2159-662X&rft.volume=55&rft.issue=9&rft.spage=1438&rft.epage=1444&rft_id=info:doi/10.2967%2Fjnumed.114.141093&rft.externalDBID=n%2Fa&rft.externalDocID=10_2967_jnumed_114_141093
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0161-5505&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0161-5505&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0161-5505&client=summon